The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity

Kidney and Blood Pressure Research

Volumn 37, Issue 2-3, 2013, Pages 124-131

  Rotkegel, Sylwia ^a   Chudek, Jerzy ^a,b   Spiechowicz Zaton, Urszula ^a   Ficek, Rafal ^a   Adamczak, Marcin ^a   Wiecek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b UNIVERSITY OF SILESIA   (Poland)

Author keywords

Hypertension; Renin angiotensin aldosterone system; Visfatin

Indexed keywords

ALDOSTERONE; C REACTIVE PROTEIN; GLUCOSE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SODIUM; TRIACYLGLYCEROL;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIETARY COMPLIANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MALE; NATRIURESIS; OBESITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SODIUM INTAKE; SODIUM RESTRICTION; STANDING; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; VISCERAL OBESITY; WAIST CIRCUMFERENCE;

EID: 84876457787     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000350066     Document Type: Article

References (25)

1. Davy K, Hall J: Obesity and hypertension: two epidemics or one. Am J Physiol Regul Integr Comp Physiol 2004;286:R803-R813
2. Olszanecka-Glinianowicz M, Madej P, Zdun D, Bozentowicz-Wikarek M, Sikora J, Chudek J, Skalba P: Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2012;162:55-61
3. Balistreri CR, Caruso C, Candore G: The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010;2010:802078
4. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y: Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72-75
5. Kokot F, Wiecek A, Adamczak M, Ulman I, Spiechowicz U, Cieplok J, Mesjasz J: Pathophysiological role of leptin in patients with chronic renal failure, in kidney transplant patients, in patients with essential hypertension, and in pregnant women in preeclampsia. Artif Organs 1999;23:70-74
6. Wiecek A, Adamczak M, Chudek J: Adiponectin-an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007;22:981-988
7. Olszanecka-Glinianowicz M, Kocelak P, Nylec M, Chudek J, Zahorska-Markiewicz B: Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012;8:214-218
8. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A, Wolzt M: Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008;38:820-826
9. Ferrari I, Palumbo I, Randazzo S, Fogari E, D'Angelo A, Cicero AF: Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res 2011;34:145-151
10. Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI: Effect of reninangiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology 2010;15:225-229
11. Radikova z, Koska j, Huckova M, Ksinatova L, Imrich R, Vigas M, Trnovec T, Langer P, Sebkova E, Klimes I: Insulin sensitivity indices: A proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes 2006;114:249-256
12. Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, Erturk H, Bingol N, Kilic S, Ozgurtas Y: Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007;21:173-175
13. Gunes F, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek M: Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012;51:553-557
14. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ischisaka T, Murakami H, Watanabe E, Takagi T, Akivoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430
15. Berndt J, Kloting N, Kralish S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M: Plasma visfatin concentrations and fat deposit-specific mRNA expression in humans. Diabetes 2005;54:2911-2916
16. Hammarstedt A, Pihlajamaki J, Rotter SV, Gogg S, Jansson PA, Laakso M, Smith U: Visfatin is an adipokine, but it is not regulates by thiazolidendiones. J. Clin Endocrinol Metab 2006;91:1181-1184
17. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ: Eleveted plasma level of visfatin/Pre-B cell colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-299
18. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, Vatish M, Lewinski A, Prelevic GM, Randeva HS: Elevated serum levels of visfatin in gestational diabetes: A comparative study across various degrees of glucose tolerance. Diabetologia 2007;50:1033-1037
19. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM: C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-2951
20. Venugopal SK, Deveraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulations 2002;106:1439-1441
21. Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, Tseng JJ, Chou MM, Sheu WH: Visfatin-induced expression of inflammatory mediators in human endothelial cells throught the NF-kappaB pathway. Int J Obes 2009;33:465-472
22. Hilgers KF, Veelken R, Kreppner I, Ganten D, Luft FC, Geiger H, Mann JF: Vascular angiotensin and the sympathetic nervous system: do they interact? Am J Physiol 1994;267:H187-194
23. Lafontan M, Berlan M: Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993;34:1057-1091
24. Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, Luscher TF, Noll G: Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacocinetics. J Am Coll Cardiol 1997;29:1607-1614
25. Sinski M, Lewandowski J, Abramczyk P, Narkiewicz K, Gaciong Z: Why study sympathetic nervous system? J Physiol Pharmacol 2006;57:79-92.